First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 24, 2024

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2028

Conditions

NSCLC (non-small Cell Lung Cancer)

Interventions

DRUG

Induction Carboplatin

Induction phase of carboplatin+etoposide+pembrolizumab followed by maintenance of Pembrolizumab+sacituzumab govitecan

Trial Locations (1)

RECRUITING

Shaare Zedek Medical Center, Jerusalem

All Listed Sponsors

lead

Nir Peled

OTHER